Cell Medica Ltd.
This article was originally published in Start Up
Executive Summary
Cell Medica is pursuing what could be considered a relatively low-tech, low-risk approach to T-cell immunotherapy. The two-year-old spin-out of Imperial Innovations Group will treat immunosuppressed bone marrow donation recipients with T cells isolated from their bone marrow donors. The company's first project is in isolating cytomegalovirus-specific T cells from donors for infusion into patients who are at particular risk of CMV infection following bone marrow transplant.